Search

Displaying results 3391 - 3400 of 7603 in total
  1. Drug

    Cortisone acetate

    go.drugbank.com/drugs/DB01380
    ApprovedInvestigational

    Cortisone acetate was first isolate in 1935 and became more widely researched in 1949. Since then, glucocorticoids such as cortisone acetate have been used to treat a number of inflammatory conditions such as endocrine, rheumatic, collag...

    Categories: Corticosteroids for Systemic Use
  2. Drug

    Mupadolimab

    go.drugbank.com/drugs/DB16488
    Investigational

    NCT04464395 and NCT04734873 assessed its use for hospitalized COVID-19 patients alone or with standard care.

    Categories: Experimental Unapproved Treatments for COVID-19
  3. Drug

    Chenodeoxycholic acid

    go.drugbank.com/drugs/DB06777
    ApprovedInvestigational

    Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body.

  4. Drug

    Dihydroquinidine barbiturate

    go.drugbank.com/drugs/DB01341
    Experimental

  5. Drug

    Calusterone

    go.drugbank.com/drugs/DB01564
    ExperimentalIllicit

    A 17-alkylated orally active androgenic steroid. A Schedule IV drug in Canada.

  6. Drug

    Carbocromen

    go.drugbank.com/drugs/DB13279
    ApprovedWithdrawn

    Carbocromen was marketed for use in Germany as a vasodilator, however, it has been discontinued due to the risk of arrhythmia development [L5635].

  7. Drug

    Glafenine

    go.drugbank.com/drugs/DB08963
    ApprovedWithdrawn

    An anthranilic acid derivative with analgesic properties used for the relief of all types of pain. Glafenine is withdrawn from the American market.

  8. Drug

    Arbaclofen

    go.drugbank.com/drugs/DB08891
    Investigational

    It has also been investigated as a treatment for spasticity due to multiple sclerosis and spinal cord injury. … Arbaclofen was investigated as a treatment for gastroesophageal reflux disease (GERD); however, with disappointing results.

  9. Drug

    GI-5005

    go.drugbank.com/drugs/DB05942
    Investigational

    GI-5005 is GlobeImmune's lead infectious disease product from its proprietary Tarmogen active immunotherapy platform for the treatment of chronic hepatitis C infection.

  10. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    Nirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors. … [A262561] Nirogacestat was approved under the brand name OGSIVEO on November 27, 2023, by the FDA for the treatment of adult patients with progressing desmoid tumors who require systemic treatment.